Compare · ECOR vs HSDT
ECOR vs HSDT
Side-by-side comparison of electroCore Inc. (ECOR) and Solana Company (HSDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and HSDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- HSDT is the larger of the two at $108.8M, about 2.2x ECOR ($48.4M).
- ECOR has been more active in the news (9 items in the past 4 weeks vs 5 for HSDT).
- HSDT has more recent analyst coverage (3 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- Solana Company
- Price
- -
- -
- Market cap
- $48.4M
- $108.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 5
- Recent ratings
- 2
- 3
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Latest ECOR
- Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
- electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- SEC Form 10-Q filed by electroCore Inc.
- electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- electroCore Announces Third Quarter 2026 Financial Results
- electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
- electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning
- electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub
- Director Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)
Latest HSDT
- SEC Form 10-Q filed by Solana Company
- Solana Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solana Company Reports Third Quarter 2026 Financial Results
- Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
- Solana Company Selected as a Strategic Enterprise by the Hong Kong SAR Government
- SEC Form 424B5 filed by Solana Company
- Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Solana Company (NASDAQ: HSDT) Announces Pricing of $15 Million Registered Direct Offering with a Global Institutional Investor
- SEC Form 4 filed by Officer Tjandrasuwita Agustina Gani
- Solana Company Announces Positions and Votes on first Solana Governance Proposals